A Call to Action for Acute Lymphoblastic Leukemia
Menée sur 1 725 patients atteints d'une leucémie lymphoblastique aiguë, dont 154 du type "Ph-like", puis in vitro et in vivo, cette étude identifie un ensemble d'anomalies génomiques susceptibles de faire l'objet d'un ciblage thérapeutique à l'aide d'inhibiteurs de tyrosine kinase chez les patients atteints d'une leucémie "Ph-like"
The cure rates for precursor B-cell acute lymphoblastic leukemia (ALL) among children have improved, but the prognosis for older patients and children with relapsed disease remains poor. Risk stratification based on clinical features and disease characteristics can improve outcomes by enabling physicians to reduce the toxicity of therapy for patients with lower-risk disease and intensify therapy for patients with higher-risk disease. The negative prognosis associated with the t(9;22) translocation, which results in expression of the BCR–ABL1 activated kinase fusion protein, is attenuated by treatment that includes tyrosine kinase inhibitors, providing a paradigm for molecularly guided therapy in patients with precursor . . .
New England Journal of Medicine , éditorial, 2013